The PROCAN-B+ study protocol: early diagnosis of prostate cancer for Black men: a multi-center, two-arm, individually randomized controlled trial of a co-produced, peer-led intervention with a qualitative process evaluation
Background Black men face double the risk of developing and dying from prostate cancer. We co-designed a peer-led intervention with Black men ( n = 13), underpinned by the Integrated Screening Action Model (I-SAM), to encourage early diagnosis of prostate cancer. The intervention is a 2-h workshop which includes peer led discussions about challenges to accessing prostate cancer health care, health education delivered by a Black GP and video testimonials from survivors, women and religious leaders. Previously, the PROCAN-B pilot study was evaluated qualitatively ( n = 40) and through a pre-post survey design ( n = 41). Qualitative findings indicated that participants found the intervention acceptable and they enjoyed taking part. Quantitative findings demonstrated significant increases in knowledge and more positive attitudes toward accessing prostate cancer health checks and PSA testing. However, the sample was small and the intervention requires more robust effectiveness testing, which is what this follow-on PROCAN-B+ trial aims to do. Methods The PROCAN-B+ trial examines the intervention's effectiveness and usability through a multi-center, two-arm, individually randomized, wait-list controlled trial in community settings across three sites: (1) North-East England including Leeds, (2) London, and (3) Scotland; with a qualitative process evaluation. Recruitment will be through community networks, using purposive and snowball-sampling, to obtain a sample of 330 participants. Participants will be individually randomized to receive the intervention immediately (intervention group), or wait-listed to receive usual care, and the intervention after 6-months (control). Members of the community will be trained to deliver the intervention. The primary outcome is decision self-efficacy, reflecting participants' confidence in their ability to engage in informed shared decision making with a doctor. Secondary outcomes include knowledge, attitudes and beliefs about prostate cancer risk and PSA testing, intentions to discuss prostate health with a doctor, self-reported discussions with a doctor, self-reported PSA testing, and doctor verified PSA-testing. Survey data will be collected at baseline, post-intervention, and 3- and 6-month follow-up. Qualitative evaluation will explore perspectives on methodology, acceptability and implementation through interviews and focus groups. If effective, the intervention may address prostate cancer inequalities by improving awareness, inform help-seeking, and early diagnosis for better outcomes. ClinicalTrial.gov registration NCT07620717 https://clinicaltrials.gov/study/NCT07620717 Registered 2 June 2026
Authors
- John Kabuye
- Rawand Jarrar (ORCID: https://orcid.org/0000-0002-9452-8249)
- Zoe Moon (ORCID: https://orcid.org/0000-0002-5242-1718)
- Olugbenga Sam Oyeniyi
- Tanimola Martins (ORCID: https://orcid.org/0000-0001-5226-4073)
- Marie K. Murphy
- Rob Horne
- Katie Robb
- Olasunkanmi Adebowale
- Scott Wilkes
- Alex McConnachie
- Greg Shaw
- Moses Apiliga
- Nathan Mwesigwa
- Tolase Jaiyeoba
- Ryan Swiers
- Olu Ogunleye
- Floor Christie-De Jong
Institutions
- University of Exeter (GB)
- NHS Greater Glasgow and Clyde (GB)
- University College London (GB)
- University of Waikato (NZ)
- University of Sunderland (GB)
- University of Glasgow (GB)
Publication Details
- Journal
- Frontiers in Public Health
- Published
- 2026-11-19
- DOI
- https://doi.org/10.3389/fpubh.2026.1944251
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00